Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

CMAB BioPharm

Request full access

Biopharmaceutical Service Firm

Suzhou Shi, ChinaFounded 2017Biotech & Life Sciences

About CMAB BioPharm

Established in 2017, CMAB Biopharma Inc. operates as a dedicated contract development and manufacturing organization (CDMO) specializing in biologic products. The company's strategic location in Suzhou's BioBAY Park in China positions it as a key partner for biopharmaceutical firms both domestically and globally.

The business model is centered on providing comprehensive, bespoke services that guide clients from the initial DNA concept to the creation of clinical-grade products. This service portfolio includes process development, manufacturing, analytical method development, and formulation for biologic drug substances and drug products. CMAB specifically targets the pre-clinical and early-stage clinical (Phase I/II) manufacturing needs of its clients, adhering to stringent global GMP standards, including those set by the NMPA, FDA, and EMA.

While specific founder details are not publicly available, the leadership team possesses substantial experience from international biopharmaceutical companies, having collectively managed over 100 CDMO projects that led to at least 40 Investigational New Drug (IND) applications. This deep industry expertise underpins the company's service offering.

CMAB Biopharma has demonstrated significant financial traction, securing a $38 million Series A financing round in January 2018, co-led by C-Bridge Capital and BioBAY. This was swiftly followed by a $34 million Series B round in April 2018, led by CD Capital. In a major corporate development, CMAB merged with BioBAY-incubation-platform-company CDMO Gene-Biocon in 2019, further enhancing its service capabilities. Subsequently, in 2021, the company was acquired by the global biopharmaceutical services giant, Porton Pharma Solutions Ltd., marking a new chapter in its growth and integration into a larger, established network.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2017
Headquarters
Suzhou Shi, China
Employees
47
Open positions
None listed
Dealroom signal
40.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Apr 2018 $34M $136M C-Bridge Capital · CD Capital —
SERIES A✓Equity / VC Jan 2018 — — CBC Group —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

CMAB BioPharm website traffic

Latest recorded traffic for CMAB BioPharm is 230 monthly website visits, down 25.8% over the last three months. CMAB BioPharm's team grew 2.2% over the past year.

Latest monthly visits230 3-month web change-25.8% 1-year team growth+2.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

CMAB BioPharm in the Suzhou Shi ecosystem

Live from Dealroom

The CMAB BioPharm office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • CBC Group
  • CD Capital
  • C-Bridge Capital
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about CMAB BioPharm on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See CMAB BioPharm’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.